Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

Images

 
Recombinant Human PD-L1/B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 2-10 μg/mL.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity
Format
Carrier-Free

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 2‑10 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-L1/B7-H1 protein
Human PD-L1
(Phe19-Thr239)
Accession # Q9NZQ7
DIEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
N-terminal Sequence
Phe19
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
CD274
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Theoretical MW
52 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
70-75 kDa, reducing conditions
Publications
Read Publications using
156-B7 in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS and NaCl.
Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

  • B7-H
  • B7H1
  • B7-H1
  • B7H1PDCD1L1
  • CD274 antigenMGC142294
  • CD274 molecule
  • CD274
  • PDCD1L1
  • PDCD1LG1
  • PDCD1LG1MGC142296
  • PDL1
  • PD-L1
  • PD-L1B7 homolog 1
  • PDL1PDCD1 ligand 1
  • programmed cell death 1 ligand 1
  • Programmed death ligand 1

Background

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on
inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).
  1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
  2. Dong, H. et al. (1999) Nat. Med. 5:1365.
  3. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
  4. Tamura, H. et al. (2001) Blood 97:1809.
  5. Chen, L. et al. (2007) J. Immunol. 178:6634.
  6. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
  7. Tsushima, F. et al. (2007) Blood 110:180.
  8. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
  9. Cao, Y. et al. (2010) Cancer Res. 71:1235.
  10. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
  11. Dong, H. et al. (2002) Nat. Med. 8:793.
  12. Azuma, T. et al. (2008) Blood 111:3635.
  13. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
  14. Park, J.-J. et al. (2010) Blood 116:1291.
  15. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
  16. Herold, M. et al. (2015) J. Immunol. 195:3584.

Customers Who Viewed This Item Also Viewed...

AF1086
Species: Hu
Applications: WB, Flow, IHC, Block, CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta)
NBP1-76770
Species: Hu, Mu, Rt
Applications: WB, ELISA, ICC/IF, IHC, IHC-P
MAB140
Species: Hu
Applications: Flow, IHC, CyTOF-ready, ELISA(Cap), ELISA(Det), Neut, ELISA(Sta)
MAB7158
Species: Hu, Mu
Applications: WB, IHC
NB100-524
Species: Hu, Mu
Applications: WB, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Flow-IC
NBP1-84550
Species: Hu
Applications: WB, IHC, IHC-P
NBP1-49045
Species: Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, Cell Depl, CyTOF-ready, InhibTFunc
NBP1-19371
Species: Hu, Mu, Rt, Ca, Rb
Applications: WB, Simple Western, ICC/IF, IHC, IHC-Fr, IHC-P
NBP1-92684
Species: Hu, Mu, Rt, Po, Bv, Eq
Applications: WB, ICC/IF, IHC
MAB342
Species: Hu
Applications: WB, AgAct
NB100-39002
Species: Hu, Mu, Rt
Applications: WB, Flow, ICC/IF, IHC, IHC-P, IP
AF165
Species: Hu
Applications: WB, Flow, CyTOF-ready
6507-IL/CF
Species: Hu
MAB69752
Species: Hu
Applications: Flow, B/N, CyTOF-ready
156-B7
Species: Hu
Applications: Bioactivity

Publications for PD-L1 (156-B7)(9)

We have publications tested in 2 confirmed species: Human, N/A.

We have publications tested in 3 applications: Bead Coupling, Bioassay, ELISA Standard.


Filter By Application
Bead Coupling
(1)
Bioassay
(4)
ELISA Standard
(3)
All Applications
Filter By Species
Human
(5)
N/A
(1)
All Species
Showing Publications 1 - 9 of 9.
Publications using 156-B7 Applications Species
UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy Anticancer Res., 2017;37(4):1947-1955. 2017 [PMID: 28373465] (ELISA Standard) ELISA Standard
E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice Mol. Cancer Ther, 2017;0(0):. 2017 [PMID: 28265006] (Bioassay, N/A) Bioassay N/A
Robert L Ferris Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk Oncoimmunology, 2016;5(10):e1200778. 2016 [PMID: 27853635] (Bead Coupling) Bead Coupling
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells Sci Rep, 2016;6(0):36722. 2016 [PMID: 27824138] (ELISA Standard, Human) ELISA Standard Human
Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane L, Ferris R PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res, 2015;75(3):508-18. 2015 [PMID: 25480946] (Bioassay, Human) Bioassay Human
Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE, 2014;9(12):e113396. 2014 [PMID: 25478957] (ELISA Standard, Human) ELISA Standard Human
Chinnadurai R, Copland I, Patel S, Galipeau J IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol, 2014;192(4):1491-501. 2014 [PMID: 24403533] (Bioassay, Human) Bioassay Human
Steidl C, Shah SP, Woolcock BW MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 2011;471(7338):377-81. 2011 [PMID: 21368758] (Bioassay, Human) Bioassay Human
Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol., 2006;177(12):8844-50. 2006 [PMID: 17142787]

Reviews for PD-L1 (156-B7) (0)

There are no reviews for PD-L1 (156-B7). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
  • 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen

FAQs for PD-L1 (156-B7) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Customers Who Bought This Also Bought

CD4 Antibody
NBP1-19371
PD-L1 Antibody
NBP1-76769

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF and receive a gift card or discount.

Bioinformatics

Gene Symbol CD274
Uniprot